PDS Stock Recent News

Scale, innovation and disciplined execution help PTEN, RIG, and PDS stand out in a slumping drilling industry.

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe

PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.

Oil drilling activity in the U.S. will be cut back due to low prices. However, drilling in Canada is robust due to structural factors, at least for now. Precision Drilling gets 2/3 of its revenue from Canada and may weather the downturn better than its U.S. focused competitors.

Phase 2: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC

PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat during the Alliance Global Partners (“A.G.P.”) Virtual Annual Healthcare Company Showcase, taking place May 21, 2025.

CALGARY, Alberta, May 15, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) is pleased to announce the results of the election of board members at its 2025 Annual and Special Meeting of Shareholders held on May 15, 2025 (the Annual Meeting). Shareholders approved the election of all eight (seven of whom are independent) of the nominee directors presented in the Company's Management Information Circular (the Circular), dated April 2, 2025.

PDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head and neck cancers linked to HPV16. The trial, which will enrol around 350 patients, is supported by the US Food and Drug Administration Fast Track designation and includes interim data readouts.

VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J.

NEWTON, Mass. & PETACH TIKVA, Israel--(BUSINESS WIRE)--CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that PDS Health, a leading integrated healthcare support organization serving more than 1,000 dental and primary care practices across the U.S., will extend its CyberArk implementation with additional machine identity security solutions. By adding CyberArk Zero Touch PKI and CyberArk Certificate Manager to its identity security program, PDS Health will moderniz.